Introduction {#ijc32176-sec-0001}
============

Approximately 10--15% of breast cancer cases are caused by hereditary genetic mutations.[1](#ijc32176-bib-0001){ref-type="ref"} The most penetrating mutations are those in the *BRCA1* and *BRCA2* (*BRCA*) genes,[2](#ijc32176-bib-0002){ref-type="ref"}, [3](#ijc32176-bib-0003){ref-type="ref"} which are essential for maintaining the genome stability. Women carrying pathogenic mutations in *BRCA1* have a 72% lifetime risk of developing breast cancer, while those with *BRCA2* mutations have a 69% risk.[4](#ijc32176-bib-0004){ref-type="ref"} Mutations in *BRCA* also increase the risk for ovarian cancer, prostate cancer, melanoma and pancreatic cancer. Identification of *BRCA* mutation carriers before the development of cancer is crucial in order to protect them from developing cancer by taking preventive measures of early cancer surveillance, chemoprevention and preventive surgery.[5](#ijc32176-bib-0005){ref-type="ref"}, [6](#ijc32176-bib-0006){ref-type="ref"}, [7](#ijc32176-bib-0007){ref-type="ref"}, [8](#ijc32176-bib-0008){ref-type="ref"}, [9](#ijc32176-bib-0009){ref-type="ref"} Extensive efforts have identified a large number of *BRCA* mutations, mainly in the Caucasian populations of Europe and North America. *BRCA* databases with well‐documented, annotated and freely accessible *BRCA* information have been developed and used worldwide as the references for diagnosis, treatment and prevention of *BRCA* associated cancers.

Studies have revealed that human *BRCA1* and *BRCA2* are rapidly evolving under positive selection to effectively protect genome stability.[10](#ijc32176-bib-0010){ref-type="ref"}, [11](#ijc32176-bib-0011){ref-type="ref"} Recent studies have further suggested that the variation in human *BRCA* could be ethnic‐specific in different ethnic populations. For example, *BRCA* variants within Latin American populations are highly heterogeneous,[12](#ijc32176-bib-0012){ref-type="ref"} and *BRCA* variants in Asian populations differ substantially from those in other populations.[13](#ijc32176-bib-0013){ref-type="ref"} Understanding the ethnic‐specificity of *BRCA* variation is important, as it can provide a precise genetic basis to study the relationship between human evolution and diseases. Furthermore, it will determine whether the Caucasian‐based *BRCA* data is adequate to serve as a universal reference to determine *BRCA* status in non‐Caucasian populations around the world, or whether the ethnicity‐based *BRCA* mutation data should be developed instead. However, the answer remains elusive owing to the lack of *BRCA* data from most of the non‐Caucasian populations.[12](#ijc32176-bib-0012){ref-type="ref"}, [13](#ijc32176-bib-0013){ref-type="ref"}, [14](#ijc32176-bib-0014){ref-type="ref"}, [15](#ijc32176-bib-0015){ref-type="ref"} For example, in the recently completed CIMBA study that collected *BRCA* data from 49 countries across six continents, the data available from any single, non‐Caucasian ethnic populations remain very limited.[15](#ijc32176-bib-0015){ref-type="ref"} To fully prove the existence of ethnic‐specific *BRCA* mutations, a comprehensive data from particular ethnic populations will be required.

The Chinese population is the largest one in the world.[16](#ijc32176-bib-0016){ref-type="ref"} Breast cancer is the most common cancer among Chinese women, with 260,000 new breast cancer cases diagnosed and 70,000 mortalities annually.[17](#ijc32176-bib-0017){ref-type="ref"} With nearly two decades of *BRCA* studies in China, in particular in the recent years owing largely to the adoption of next‐generation sequencing technologies, *BRCA* data exclusively derived from the Chinese population are increasingly reported.[17](#ijc32176-bib-0017){ref-type="ref"}, [18](#ijc32176-bib-0018){ref-type="ref"}, [19](#ijc32176-bib-0019){ref-type="ref"} Thus, the Chinese population can serve as an ideal model to test the presence of ethnic‐specific *BRCA* mutations. Through a comprehensive data mining, standardization and annotation, we collected nearly all *BRCA* variant data currently available for the Chinese population and developed the data into a public database dbBRCA‐Chinese (<https://dbBRCA-Chinese.fhs.umac.mo>). Using this rich data set, we studied the similarities and differences in *BRCA* variation between Chinese and non‐Chinese populations. The data from our study provides a convincing evidence for the existence of ethnic‐specific *BRCA* mutation. Here, we report detailed information from the study.

Materials and Methods {#ijc32176-sec-0002}
=====================

Variant data collection and analysis {#ijc32176-sec-0003}
------------------------------------

We searched for resources reporting *BRCA* variation data from individuals of Chinese ethnicity, including publications in PubMed, the China National Knowledge Infrastructure (CNKI) database (<http://oversea.cnki.net/kns55/default.aspx>) and WanFang (<http://www.wanfangdata.com/COJ/intr.asp#China> Online), as well as Chinese‐derived *BRCA* variants in existing BRCA databases.[19](#ijc32176-bib-0019){ref-type="ref"} For the collected *BRCA* variants, we performed extensive standardization and reannotation, following HGVS[20](#ijc32176-bib-0020){ref-type="ref"} and ACMG guidelines.[21](#ijc32176-bib-0021){ref-type="ref"} The reference sequences used for *BRCA1* analysis were: cDNA NM_007294.3, protein NP_009225.1, genome hg19, BIC cDNA: U14680.1 and BIC protein: AAA73985.1; those used for *BRCA2* were: cDNA NM_000059.3, protein NP_000050.2, genome hg19, BIC cDNA: U43746.1 and BIC protein: AAB07223.1, respectively[22](#ijc32176-bib-0022){ref-type="ref"} (<https://doi.org/10.1093/nar/gkw1070>). The transcript‐oriented position of each variant was converted to its respective genome position in hg19 using the Position Converter tool in Mutalyzer,[23](#ijc32176-bib-0023){ref-type="ref"} and the consistency with HGVS nomenclature was confirmed using the Name Checker DNA tool.[24](#ijc32176-bib-0024){ref-type="ref"} The variants were annotated using ANNOVAR with eight reference databases namely: RefGene, dbSNP (version 150), 1000genome, ESP6500, ExAC, ClinVar, InterVar and DBNSFP.[24](#ijc32176-bib-0024){ref-type="ref"} Following *BRCA* databases were used for the comparative analysis: BIC [25](#ijc32176-bib-0025){ref-type="ref"} (<https://research.nhgri.nih.gov/bic/>, accessed February 20, 2018), ClinVar[26](#ijc32176-bib-0026){ref-type="ref"}(<http://www.ncbi.nlm.nih.gov/clinvar/>, accessed February 20, 2018), BRCA Exchange (<http://brcaexchange.org>, accessed February 20, 2018), ENIGMA[27](#ijc32176-bib-0027){ref-type="ref"} (downloaded from BED database, <http://brcaexchange.org>, accessed February 20, 2018), BMD (<http://www.arup.utah.edu/database/BRCA/Home/BRCA1_landing.php>,<http://www.arup.utah.edu/database/BRCA/Home/BRCA2_landing.php>)(<https://www.aruplab.com/topics/breast-cancer/brcadatabase>, accessed February 20, 2018), LOVD[28](#ijc32176-bib-0028){ref-type="ref"} (<http://www.lovd.nl/3.0/home>, accessed February 20, 2018) and CIMBA.[15](#ijc32176-bib-0015){ref-type="ref"} The Chinese variants present in these databases were classified as known variants; those absent were classified as novel variants and deposited in ClinVar database[29](#ijc32176-bib-0029){ref-type="ref"} (accession number nstd165). Five categories based on ACMG guidelines were used: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign for the variant classification of known variants using ClinVar database.[30](#ijc32176-bib-0030){ref-type="ref"}, [36](#ijc32176-bib-0036){ref-type="ref"} For those variants not matched with the variant list using the above‐mentioned resources, their classifications were predicted from InterVar database using ANNOVAR annotation tool.[30](#ijc32176-bib-0030){ref-type="ref"} For these variants not being able to classified, they were included as "Unclassified" group. *BRCA* variants in Latin population were extracted from Villarreal‐Garza et al.,[12](#ijc32176-bib-0012){ref-type="ref"} *BRCA* variants in Asian populations were extracted from,[13](#ijc32176-bib-0013){ref-type="ref"} and *BRCA* variants in the Indian population were extracted from,[13](#ijc32176-bib-0013){ref-type="ref"}, [31](#ijc32176-bib-0031){ref-type="ref"} respectively.

Statistical data analysis {#ijc32176-sec-0004}
-------------------------

Fisher\'s exact test was used to analyze the differences between the Chinese and non‐Chinese variant data. *p* \< 0.05 was considered as significant difference.

Results {#ijc32176-sec-0005}
=======

Collection of Chinese BRCA data {#ijc32176-sec-0006}
-------------------------------

The majority of Chinese *BRCA* variation data was gathered from mainland China (90.2%), and the remainder were from Hong Kong (6.4%), Taiwan (1.6%), Singapore (0.9) and Malaysia (0.4%) (Table [S1](#ijc32176-supitem-0001){ref-type="supplementary-material"}A, [S1](#ijc32176-supitem-0001){ref-type="supplementary-material"}B, Supporting Information). In total, 31,689 cases with Chinese ethnicity were tested for *BRCA* mutations and their results were reported between 1999 and 2017; of these, 69.3% were reported between 2016 and 2017. Nearly all *BRCA* variants were from breast and/or ovarian cancer patients under different clinical criteria, except for four variants that were derived from 1,043 healthy control individuals.[32](#ijc32176-bib-0032){ref-type="ref"}

We collected and summarized the clinical information reported from each of the reference studies (Fig. [S1](#ijc32176-supitem-0010){ref-type="supplementary-material"} and Table [S2](#ijc32176-supitem-0002){ref-type="supplementary-material"}, Supporting Information). The data showed several unique features as follows: 1). BMI is considered as one of the risk factors for breast cancer. However, according to our data, 83.7% of Chinese patients were within the normal range of 18.5--22.9 BMI and 10.5% were seen to have even lower than 18.5 BMI, indicating that obesity had no significant role in increasing risk for breast and ovarian cancer in these Chinese patients; 2). Family history is considered as a high‐risk factor for hereditary breast cancer. However, 72.3% of patients from our study did not report any family history of cancer, suggesting that family history was not an essential factor in this disease cohort; 3). Stage II breast cancer cases accounted for 66.2% whereas stage I cases only 6.3%, indicating the lack of earlier diagnosis.

A total of 3,791 *BRCA* mutation carriers were identified (12%, 2,123 *BRCA1* and 1,688 *BRCA2*), of which 1,978 carriers (52.2%, 990 *BRCA1* and 988 *BRCA2*) were within the clinically reported mutation categories of pathogenic or likely pathogenic. By standardizing and re‐annotating all the variants following Human Genome Variation Society (HGVS)‐recommended nomenclature, we identified a total of 1,088 distinct *BRCA* variants (557 in *BRCA1* and 531 in *BRCA2*) of which 519 (47.7%, 278 in *BRCA1* and 241 in *BRCA2*) were recurrent, and 50% were either detected or validated by Sanger sequencing (Tables [S4](#ijc32176-supitem-0004){ref-type="supplementary-material"}--[S5](#ijc32176-supitem-0005){ref-type="supplementary-material"}, Supporting Information). Except the 26 variants specifically from Uygur ethnic population, all variants were from Han Chinese population. We developed the dbBRCA‐Chinese database as an open source to host the entire set of *BRCA* variants and their annotation information ([https://dbBRCA-Chinese.fhs.umac.mo](https://dbbrca-chinese.fhs.umac.mo)).

General features of Chinese BRCA data {#ijc32176-sec-0007}
-------------------------------------

### *Age and abundance of variants* {#ijc32176-sec-0008}

The 1,088 BRCA variants were distributed with different frequencies among the 3,791 *BRCA* variant carriers. The age distribution data show that 52.3% of the cancer developed at early age (\<40 years) in these *BRCA* variant carriers (Table [S1](#ijc32176-supitem-0001){ref-type="supplementary-material"}C, Supporting Information). About half of the variants were detected only once in single individuals (46.5% in *BRCA1*, 54.6% in *BRCA2*), and the rest variants were distributed between 2 to 100 individuals with increased frequencies (Table [S1](#ijc32176-supitem-0001){ref-type="supplementary-material"}D, Supporting Information).

### *Pathogenic and nonpathogenic variants* {#ijc32176-sec-0009}

We classified the *BRCA* variants into five classes---pathogenic, likely pathogenic, uncertain significance, likely benign, and benign---following the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. Pathogenic and likely pathogenic variants, which are clinically reportable, accounted for 46% of *BRCA1* variants and 52% of *BRCA2* variants. Such higher rates do not necessarily imply high *BRCA* variation rate in Chinese breast and ovarian cancer patient population but reflect the fact that the cancer patients included in many of the studies were selected from high‐risk patients of strong family history or early age of cancer development. Importantly, 13% and 8% of *BRCA1* and *BRCA2* were classified as of uncertain significance, and 30% of both *BRCA1* and *BRCA2* variants remained as unclassified variants (Fig. [1](#ijc32176-fig-0001){ref-type="fig"} *a*). This fact indicates that much effort needs to be made in order to determine the function of these *BRCA* variants existing in Chinese population.

![*BRCA* data. (*a*) Clinical classification of Chinese *BRCA* data as pathogenic, likely pathogenic, uncertain significance, likely benign, benign and unclassified. The pathogenic and likely pathogenic variants accounted for 49.5%. (*b*) Relationship between population sizes and their contribution to current *BRCA* data. The proportions of different human ethnic populations were from the database ([http://www.worldometers.info/world‐population/](http://www.worldometers.info/world-population/)), the ethnic origins of *BRCA* data were from different *BRCA* databases. It shows that the current *BRCA* data is not proportional to the human ethnic populations. (*c*) Comparison of *BRCA* data between Chinese and non‐Chinese populations. A total of 557 *BRCA1* and 531 *BRCA2* Chinese variants were compared to 6,344 *BRCA1* and 8,886 *BRCA2* non‐Chinese variants compiled from all existing *BRCA* databases. The results show that 38% of Chinese *BRCA* variants were present only in the Chinese population.](IJC-145-962-g001){#ijc32176-fig-0001}

Ethnic origins of current BRCA data {#ijc32176-sec-0010}
-----------------------------------

We compiled ethnic origins of currently existing *BRCA* variation data to know the status of *BRCA* study across ethnic human populations. By combining the *BRCA* variants from the Breast Cancer Information Core (BIC), ClinVar, *BRCA* Exchange Database (BED), *BRCA1* and *BRCA2* Mutation Database (BMD), Leiden Open Variation Database (LOVD) and ENIGMA (Evidence‐based Network for the Interpretation of Germline Mutant Alleles), we generated a single *BRCA* variation data set containing 6,343 distinct *BRCA1* and 8,884 distinct *BRCA2* variants (S6A). Classification of the ethnic origins of these variants showed that 62% were from Caucasian populations and 15% from the Ashkenazi Jewish population. The remaining 23% were originated from non‐Chinese Asian (13%), Latino (5%), African (3%), and Chinese (2%) populations (Fig. [1](#ijc32176-fig-0001){ref-type="fig"} *b* and Tables [S6](#ijc32176-supitem-0006){ref-type="supplementary-material"}B, [S6](#ijc32176-supitem-0006){ref-type="supplementary-material"}C, Supporting Information). Of the 5,925 CIMBA *BRCA* variants data with defined ethnicities, 80.2% were from Caucasian, 2.4% from Ashkenazi Jews, 10.8% from Asian, 3.8% from Hispanic and 2.8% from African American.[15](#ijc32176-bib-0015){ref-type="ref"} The analysis shows that the current *BRCA* variant data contains very limited information from non‐Caucasian populations.

We performed the multi‐layer analyses to investigate the similarities and differences in *BRCA* variation between Chinese and non‐Chinese populations.

Comparison with existing *BRCA* data {#ijc32176-sec-0011}
------------------------------------

In order to determine the similarities and differences of *BRCA* variation between Chinese and non‐Chinese populations, we made a comprehensive comparison between Chinese and any available non‐Chinese *BRCA* data as represented below. The rationale for comparing with each database are:GnomAD: It contains extensive normal population variation data collected from human population by the largest exome and whole‐genome sequencing projects. The comparison aimed to determine the similarities and differences of the normal *BRCA* variants present between Chinese and non‐Chinese populations;BIC, BED, BMD, ClinVar, ENIGMA and LOVD: These are the major *BRCA* databases, with the data mostly derived from Caucasians as indicated by our analysis (Fig. [1](#ijc32176-fig-0001){ref-type="fig"} *b*). Comparison with these databases aimed to determine the similarities and differences of *BRCA* mutation between Chinese and Caucasian (mostly) populations;CIMBA data: It contains *BRCA* data collected from 49 countries across six continents. The comparison aimed to determine the similarities and differences between Chinese and worldwide non‐Chinese populations including more non‐Caucasian data;Latin America and the Caribbean data: The data were from Latin American population of Argentina, Bahamas, Brazil, Chile, Colombia, Costa Rica, Cuba, Mexico, Peru, Puerto Rico, Uruguay, Venezuela and the Hispanic population in the United States.[12](#ijc32176-bib-0012){ref-type="ref"} The comparison aimed to determine the similarities and differences between Chinese and Latin America populations;Non‐Chinese Asian populations: *BRCA* data are available from Bangladeshi, Filipino, Iranian, Israeli, Japanese, Korean, Lebanese, Malay, Oman, Pakistani, Sri Lankan, Thai and Turkish populations.[13](#ijc32176-bib-0013){ref-type="ref"} These populations were genetically and geographically closer to the Chinese population than other non‐Chinese populations. The comparison aimed to determine the similarities and differences between Chinese and the non‐Chinese Asian populations;Indian population: India has the 2nd largest population in the world, with highly diversified genetic background. Several large‐scale *BRCA* studies were reported recently with substantial *BRCA* data collected from the Indian patients.[13](#ijc32176-bib-0013){ref-type="ref"}, [31](#ijc32176-bib-0031){ref-type="ref"} The comparison aimed to determine the similarities and differences between Chinese and Indian populations, the two largest populations in the world.

### *GnomAD* {#ijc32176-sec-0012}

Matching the Chinese *BRCA* data with those in GnomAD from the largest exome and whole‐genome sequence data collection[33](#ijc32176-bib-0033){ref-type="ref"} showed that only 76 of the 557 (13.6%) Chinese *BRCA1* had matches in 2,476 (3%) *BRCA1* variants in GnomAD and 97 of the 531 (18.2%) Chinese *BRCA2* had matches in 3,674 variants (2.6%) in GnomAD. The results indicate that the vast majority of the Chinese *BRCA* variants were not present in the population data provided by current exome and whole‐genome sequencing studies (Table [1](#ijc32176-tbl-0001){ref-type="table"}A and Table [S7](#ijc32176-supitem-0007){ref-type="supplementary-material"}A, Supporting Information). For those with the matches, their abundance as judged by the East Asia population frequencies were mostly at lower levels \[62/76 (81.5%) *BRCA1* variants and 73/97 (72.3%) *BRCA2* variants \<0.001\], highlighting their pathogenic potential.

###### 

Comparison of *BRCA* variants between Chinese and other populations

                                                                        *BRCA1* variants   *BRCA2* variants                          
  --------------------------------------------------------------------- ------------------ ------------------ ------- -------- ----- -------
  A. GnomAD database                                                                                                                 
                                                                        2,496              76                 0.136   3,674    97    0.182
  B. Multiple *BRCA* databases[3](#ijc32176-note-0004){ref-type="fn"}                                                                
  Total                                                                 22,095             371                0.666   28,648   305   0.574
  BED                                                                   7,810              347                0.601   10,378   277   0.522
  BIC                                                                   1,702              207                0.359   1,916    159   0.299
  BMD                                                                   1,271              179                0.310   1,321    122   0.230
  Clinvar                                                               5,537              355                0.601   7,688    286   0.539
  ENIGMA                                                                2,712              206                0.357   3,442    178   0.335
  LOVD                                                                  3,063              164                0.284   3,903    131   0.247
  C. CIMBA *BRCA* variants                                                                                                           
                                                                        1,651              91                 0.163   1,731    71    0.134
  D. Latin American *BRCA* variants                                                                                                  
                                                                        75                 13                 0.023   76       11    0.021
                                                                                                                                     
  E. Asian *BRCA* variants                                                                                                           
                                                                        276                121                0.217   266      111   0.209
  F. Indian *BRCA* variants[4](#ijc32176-note-0005){ref-type="fn"}                                                                   
                                                                        89                 23                 0.041   41       2     0.004

Total refers to the numbers in each reference database.

Proportion = Shared variants / total variants (557 in *BRCA1* or 531 in *BRCA2*) in Chinese population.

Variants can be overlapped among different databases and populations.

Indian *BRCA* variants in Refs. [13](#ijc32176-bib-0013){ref-type="ref"}, [22](#ijc32176-bib-0022){ref-type="ref"} were combined for the comparison.

### *BIC, ClinVar, BED, BMD, LOVD and ENIGMA* {#ijc32176-sec-0013}

Comparing the Chinese *BRCA* data with non‐Chinese *BRCA* data in these major *BRCA* databases shows that 38% of *BRCA* variants were present only in the Chinese population \[186 (33.4%) of 557 *BRCA1* variants and 226 (42.6%) of 531 *BRCA2* variants\] (Fig. [1](#ijc32176-fig-0001){ref-type="fig"} *c*, Table [1](#ijc32176-tbl-0001){ref-type="table"}B). Of all databases used for the comparison, the ClinVar database had the highest matching rates of 60.1% and 53.4% in *BRCA1* and *BRCA2*, respectively due to its large data collection.

### *CIMBA* {#ijc32176-sec-0014}

Comparing the Chinese *BRCA* data with the recent CIMBA data enriching non‐Caucasian data shows that 17.6% of the 1,088 Chinese *BRCA* variants had matches \[BRCA1: 106/557 (19%) and BRCA2: 86/531 (16.2%). There are 15 Chinese *BRCA1* variants and 16 Chinese *BRCA2* variants included in both our Chinese data and the CIMBA data. These shared Chinese variants were removed in order to know the similarity and differences between Chinese and non‐Chinese populations included in the CIMBA data. After the removal, the overall matched rate decreased to 14.9% \[BRCA1: 91/557 (16.3%) and BRCA2: 71/531 (13.4%)\] (Table [1](#ijc32176-tbl-0001){ref-type="table"}C and Table [S7](#ijc32176-supitem-0007){ref-type="supplementary-material"}B, Supporting Information).

### *Latin America and the Caribbean data* {#ijc32176-sec-0015}

Comparing the Chinese *BRCA* data with those from Latin America and the Caribbean found that 97.8% of total variants \[544 (97.7%) *BRCA1* variants and 520 (97.9%) *BRCA2*\] were specific only to the Chinese population (Table [1](#ijc32176-tbl-0001){ref-type="table"}D and Table [S7](#ijc32176-supitem-0007){ref-type="supplementary-material"}C, Supporting Information).

### *Non‐Chinese Asian populations* {#ijc32176-sec-0016}

Comparing the Chinese *BRCA* data with those in non‐Chinese Asian populations found that 78.6% of total variants \[436 (78.2%) of *BRCA1* and 420 (79.2%) of *BRCA2*\] were present only in the Chinese population (Table [1](#ijc32176-tbl-0001){ref-type="table"}E and Table [S7](#ijc32176-supitem-0007){ref-type="supplementary-material"}D, Supporting Information).

### *Indian population* {#ijc32176-sec-0017}

Comparison shows that only 23 (4.1%) *BRCA1* and two (0.4%) *BRCA2* variants were shared between the Chinese and Indian populations (Table [1](#ijc32176-tbl-0001){ref-type="table"}F and Table [S7](#ijc32176-supitem-0007){ref-type="supplementary-material"}E, Supporting Information).

Through these extensive comparisons, we were able to determine that around 40% of the BRCA data in Chinese was explicit and absent from the current *BRCA* data derived from non‐Chinese population.

Comparison in exon distribution {#ijc32176-sec-0018}
-------------------------------

We compared the variant distribution across *BRCA1* and *BRCA2* exons between Chinese and non‐Chinese populations using the data from BIC database as a testing model. For both *BRCA1* and *BRCA2*, the distribution of variants differed significantly in multiple exons between the two data sets (Fig. [S2](#ijc32176-supitem-0011){ref-type="supplementary-material"}, Supporting Information). For *BRCA1*, the proportions of variants in exons 2, 11D, 16, 20 and 24 were higher in the BIC data than in the Chinese data, whereas the proportions in exons 11B and 11C in the Chinese data were significantly higher than in the BIC data; in *BRCA2*, the proportions in exons 11A, 25 and 27 were higher in the BIC data than in the Chinese data, whereas the proportions in exons 2, 11F, 14, 21 and 22 were higher in the Chinese data than in the BIC data, respectively. The results show the presence of differences of exon distribution between Chinese and non‐Chinese *BRCA* variants.

Comparison in base changes and variant types {#ijc32176-sec-0019}
--------------------------------------------

We compared single‐base changes and other variant types between Chinese and BIC data. The results show the significant differences present in multiple types of base changes between the two data sets, including G \> A, C \> T and delT in *BRCA1*, and A \> C, delA, delG and delC in *BRCA2*. In *BRCA1*, delT had higher frequency in the Chinese population than in the BIC data (6.8% *versus* 3.5%, *p* \< 0.0034); in *BRCA2*, delA, delG and delC were more frequent in the Chinese data than in the BIC data (11.5% *versus* 4.1%, 6.7% *versus* 1.6% and 5.1% *versus* 2.4%, respectively, *p* \< 0.000, 0.000, 0.004, accordingly) (Table [2](#ijc32176-tbl-0002){ref-type="table"}A). Significant differences were also present in the missense, nonsense, stop gain, splice variants and intronic variant types in both *BRCA1* and *BRCA2*, and in frameshifts in *BRCA2* (Table [2](#ijc32176-tbl-0002){ref-type="table"}B).

###### 

Comparison of *BRCA* variation types between Chinese and BIC data

                                                                       *BRCA1*   *BRCA2*                                                               
  -------------------------------------------------------------------- --------- --------- ------- ------- ------------- ----- ------- ------- ------- -------------
  A. Changes in single base                                                                                                                            
  A \> G                                                               36        0.085     155     0.107   0.540         37    0.112   269     0.164   0.084
  A \> C                                                               10        0.024     39      0.027   0.867         4     0.012   74      0.045   ***0.003***
  A \> T                                                               28        0.066     54      0.037   0.062         10    0.030   65      0.040   0.438
  G \> A                                                               46        0.108     204     0.141   ***0.026***   37    0.112   199     0.121   0.644
  G \> C                                                               12        0.028     57      0.039   0.479         6     0.018   58      0.035   0.126
  G \> T                                                               39        0.092     117     0.081   0.697         23    0.069   93      0.057   0.700
  C \> A                                                               11        0.026     57      0.039   0.200         13    0.039   56      0.034   0.627
  C \> G                                                               19        0.045     67      0.046   0.436         21    0.063   93      0.057   0.700
  C \> T                                                               61        0.144     167     0.115   ***0.042***   44    0.133   192     0.117   0.461
  T \> A                                                               11        0.026     43      0.030   0.752         6     0.018   52      0.032   0.214
  T \> G                                                               13        0.031     59      0.041   0.262         11    0.033   85      0.052   0.093
  T \> C                                                               23        0.054     93      0.064   1.000         11    0.033   108     0.066   0.061
  insA                                                                 13        0.031     57      0.039   0.479         7     0.021   55      0.034   0.301
  insG                                                                 4         0.009     19      0.013   0.815         1     0.003   15      0.009   0.499
  insC                                                                 3         0.007     11      0.008   0.745         1     0.003   5       0.003   0.339
  insT                                                                 2         0.005     24      0.017   0.271         5     0.015   37      0.023   0.135
  delA                                                                 25        0.059     86      0.059   0.910         38    0.115   67      0.041   ***0.000***
  delG                                                                 24        0.056     49      0.034   0.052         22    0.066   26      0.016   ***0.000***
  delC                                                                 16        0.038     41      0.028   0.529         17    0.051   40      0.024   ***0.004***
  delT                                                                 29        0.068     50      0.035   ***0.003***   17    0.051   52      0.032   0.101
  Sub‐total                                                            425                 1,449                         331           1,641           
  B. Changes of variant types[1](#ijc32176-note-0006){ref-type="fn"}                                                                                   
  Frameshift                                                           214       0.420     555     0.318   0.056         286   0.571   586     0.295   ***0.000***
  Missense                                                             130       0.255     609     0.349   ***0.000***   76    0.152   889     0.447   ***0.000***
  Nonsense                                                             10        0.020     201     0.115   ***0.000***   2     0.004   187     0.094   ***0.000***
  Stop gain                                                            88        0.173     ‐       0.000   ***0.000***   98    0.196   ‐       0.000   ***0.000***
  Splice                                                               31        0.061     5       0.003   ***0.000***   13    0.026   3       0.002   ***0.000***
  Intron                                                               6         0.012     292     0.167   ***0.000***   ‐     0.000   196     0.099   ***0.000***
  Inframe deletion                                                     6         0.012     26      0.015   0.540         3     0.006   27      0.014   0.177
  Inframe insertion                                                    ‐         0.000     1       0.001   1.000         ‐     0.000   4       0.002   0.584
  Synonymous                                                           25        0.049     51      0.029   0.142         23    0.046   82      0.041   0.717
  Sub‐total                                                            510                 1,746                         501           1,987           

To comprimise naming differences between Chinese data and BIC data for comparison, the names in Chinese data were converted as: Frameshift deletion and frameshift insertion were combined as frameshift; Nonsynonymous SNV and missense were combined as Missense, Nonframeshift deletion was converted as In Frame Deletion, Splice site to Splice. Statistical comparison was performed using Fisher\'s exact test.

Comparison in clinical categories {#ijc32176-sec-0020}
---------------------------------

We compared the clinical categories: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign between Chinese *BRCA* data and BIC data. The results showed significant differences in multiple categories between the two data sets. For example, 12.7% of *BRCA1* variants in Chinese were variants of uncertain significance, which was much higher than the value of 0.57% in the BIC data (*p* \< 0.0000); the proportion of *BRCA2* pathogenic variants in the Chinese population was also significantly higher than that in the BIC data (*p* \< 0.0005), and the proportions of unclassified variants in both *BRCA1* and *BRCA2* were much higher in the BIC data than in the Chinese variants (Table [3](#ijc32176-tbl-0003){ref-type="table"}).

###### 

Comparison of Clinical classification between Chinese and BIC BRCA variants

                      *BRCA1*   *BRCA2*                                                         
  ------------------- --------- --------- ------- ------- ------- ----- ------- ------- ------- -------
  Pathogenic          233       0.418     729     0.417   0.248   247   0.465   753     0.378   0.000
  Likely pathogenic   25        0.045     ‐                       35    0.066   ‐       ‐       ‐
  Uncertain signi.    71        0.127     10      0.006   0.000   44    0.083   4       0.002   0.000
  Likely benign       25        0.045     ‐       ‐       ‐       15    0.028   ‐       ‐       ‐
  Benign              37        0.066     23      0.013   0.000   31    0.058   49      0.025   0.001
  Unclassified        166       0.298     988     0.565   0.000   159   0.299   1,188   0.596   0.000
  Total               557                 1,750                   531           1,994           

Comparison in founder mutations {#ijc32176-sec-0021}
-------------------------------

Firstly, we checked if the Chinese variant data contained any *BRCA* founder mutations known in other populations, including *BRCA1* c.66_67delAG (185delAG), c.5263_5264insC (5382insC), and *BRCA2* c.5946delT (6174delT) in Ashkenazi Jews;[34](#ijc32176-bib-0034){ref-type="ref"} *BRCA1* c.‐58C \> G (C61G), c.4153delA (c.4035delA), and c.5263_5264insC (5382insC) in Poles;[35](#ijc32176-bib-0035){ref-type="ref"} *BRCA1* c.303 T \> G, c.1623dupG, c.4122_4123delTG and c.5324 T \> G in Africans;[14](#ijc32176-bib-0014){ref-type="ref"} *BRCA1* ex9‐12del in Mexicans,[36](#ijc32176-bib-0036){ref-type="ref"} *BRCA1* 390C \> A in Koreans and Japanese; and *BRCA1* c.470_471delCT, *BRCA2* c.7480C \> T in Koreans.[37](#ijc32176-bib-0037){ref-type="ref"} We observed that many of these founder mutations were either absent or present at low prevalence, hence they could not be considered as founder mutations in the Chinese population. Secondly, we searched for potential *BRCA* founder mutation candidates in the Chinese population by referring to 1) the abundance as calculated by the total number of variant carriers divided by the total number of individuals tested although haplotype data will be required to finally determine the true founder mutations; and 2) additional criteria for removing the variants unlikely to be founder mutations in order to focus on the variants as potential candidates: more than 100 tested individuals (a founder mutation should have a reasonable prevalence in a given population. 100 was set as a minimal cut‐off for the population size); at least two detected variant carriers (as a founder mutation, it cannot be only present in a single individual. Therefore, 2 cases were set as the minimal number of mutation carriers. In this way, all variants detected only in single individuals will be eliminated); carrier frequency \> 1% (a precondition for founder mutation as pathogenic one is its lower population frequency in population. We set 1% of mutation carrier as the minimal cut‐off to eliminate these with high population frequency, which are mostly normal polymorphism); and variants in the categories of pathogenic, likely pathogenic, uncertain significance, or unclassified (Founder mutations must be pathogenic. Restricted the candidates to these classes will narrow down the founder mutation candidates by eliminating the benign and likely benign variants as they do not increase cancer risk). Using these conditions, we tested whether the data could support the Chinese *BRCA* founder mutations proposed by previous studies including *BRCA1* c.981_982delAT (1100delAT),[38](#ijc32176-bib-0038){ref-type="ref"} *BRCA1* 1081delT(1081delG),[39](#ijc32176-bib-0039){ref-type="ref"} *BRCA1*c.5154G \> A and *BRCA1*c.5468‐1del8;[40](#ijc32176-bib-0040){ref-type="ref"} and *BRCA2* c.3109C \> T, *BRCA2* c.7436_7805del370 and *BRCA2*c.9097_9098insA.[38](#ijc32176-bib-0038){ref-type="ref"} With an exception for *BRCA1*c.5154G \> A variant, our data do not support the above‐mentioned variants as the founder mutations. Next, we searched for high‐frequency variants meeting the same criteria as above and identified a total of 16 pathogenic, two likely pathogenic, 22 unclassified variants, and five of uncertain significance in *BRCA1*; and ten pathogenic, one likely pathogenic, and 11 unclassified variants in *BRCA2* (Table [4](#ijc32176-tbl-0004){ref-type="table"} and Table [S8](#ijc32176-supitem-0008){ref-type="supplementary-material"}, Supporting Information), respectively. The higher prevalence and clinical pathogenicity of these variants supported them as potential candidates for *BRCA1* and *BRCA2* founder mutations in the Chinese population. Despite of the higher prevalence, the unclassified variants or those of uncertain significance cannot be regarded as potential founder mutations unless their pathogenicity is determined.

###### 

High frequenct *BRCA* variants in Chinese population

                                                                                                                                         MAF                   
  ------------------------ ------ ---- ------- ---------- --------------------------------------- -------------------------------------- ------------- ------- ----------------------
  *BRCA1*                                                                                                                                                      
  Pathogenic               266    15   0.056   16         c.5154G \> A                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Stop gain
  Pathogenic               118    3    0.025   11D        c.4258C \> T                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Stop gain
  Pathogenic               124    3    0.024   11C        c.3296delC                              BIC\|BMD\|ClinVar\|BED\|LOVD\|ENIGMA   ‐             ‐       Frameshift deletion
  Pathogenic               125    3    0.024   21         c.5533_5540delATTGGGCA/delTACCAGTG      ‐                                      ‐             ‐       Frameshift deletion
  Pathogenic               313    6    0.019   11D        c.3640G \> T                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Stop gain
  Pathogenic               291    5    0.017   11B        c.1945G \> T                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Stop gain
  Pathogenic               118    2    0.017   2          c.213‐12A \> G                          BIC\|BMD\|LOVD\|ClinVar\|BED           ‐             ‐       ‐
  Pathogenic               257    4    0.016   16         c.5161C \> T                            BMD\|LOVD\|ClinVar\|BED\|ENIGMA        ‐             ‐       Stop gain
  Pathogenic               130    2    0.015   11A        c.1066C \> T                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Nonsense
  Pathogenic               517    7    0.014   18         c.5332+1G \> C                          BMD\|ClinVar\|BED                      ‐             ‐       Splice site
  Pathogenic               739    10   0.014   11B        c.2275C \> T                            BIC\|BMD\|LOVD\|ClinVar\|BED\|ENIGMA   ‐             ‐       Stop gain
  Pathogenic               1910   25   0.013   6          c.470_471delCT                          BIC\|BMD\|ClinVar\|BED\|ENIGMA         ‐             ‐       Frameshift deletion
  Pathogenic               643    7    0.011   15         c.4986+1G \> A                          ClinVar\|BIC\|BED\|BMD                 ‐             ‐       Splice site
  Pathogenic               190    2    0.011   2          c.68_69delAG                            ClinVar\|ENIGMA\|LOVD\|BIC\|BED\|BMD   ‐             ‐       Frameshift deletion
  Pathogenic               496    5    0.010   17         c.5267_5268insC                         ClinVar\|BED\|LOVD\|ENIGMA             ‐             ‐       Frameshift insertion
  Likely pathogenic        172    3    0.017   11A        c.1036C \> T                            BIC\|LOVD\|ClinVar\|BED                ‐             ‐       Nonsynonymous SNV
  Lilkely pathogenic       310    3    0.010   11C        c.2952delT                              BMD\|ClinVar\|BED\|ENIGMA              ‐             ‐       Frameshift deletion
  Uncertain significance   127    3    0.024   11C        c.3432G \> T                            BIC\|LOVD\|ClinVar\|BED                ‐             ‐       Nonsynonymous SNV
  Uncertain significance   193    4    0.021   2          c.‐2A \> T                              BIC\|ClinVar                           ‐             ‐       ‐
  Uncertain significance   214    3    0.014   11C        c.2941C \> T                            ‐                                      ‐             ‐       Nonsynonymous SNV
  Uncertain significance   310    4    0.013   11B        c.1934C \> A                            BIC\|LOVD\|ClinVar\|BED                ‐             ‐       Nonsynonymous SNV
  Uncertain significance   591    6    0.010   11D        c.3488C \> T                            BIC\|ClinVar\|BED                      0.000199681   0.001   Nonsynonymous SNV
  Unclassified             836    45   0.054   11C        c.2790delT                              ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             935    29   0.031   11C        c.3232C \> G                            ‐                                      ‐             ‐       Nonsynonymous SNV
  Unclassified             135    3    0.022   11C        c.3180insA                              ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             139    3    0.022   11B        c.2010_2011insTG                        ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             141    3    0.021   2          c.‐7G \> A                              ‐                                      ‐             ‐       ‐
  Unclassified             320    5    0.016   11C        c.3420_3421insT                         ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             133    2    0.015   11D        c.3780_3781delAG/c.3780_3781delAT       ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             139    2    0.014   3          c.302‐66 T \> A                         ‐                                      ‐             ‐       ‐
  Unclassified             139    2    0.014   7          c.548‐32A \> G                          BED\|LOVD                              ‐             ‐       ‐
  Unclassified             139    2    0.014   7          c.548‐37A \> T                          ‐                                      ‐             ‐       ‐
  Unclassified             139    2    0.014   11D        c.4096+112G \> T                        ‐                                      ‐             ‐       ‐
  Unclassified             495    7    0.014   11D        c.3694_3695insAA                        ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             214    3    0.014   11C        c.2939 T \> A                           ‐                                      ‐             ‐       Nonsynonymous SNV
  Unclassified             430    6    0.014   11B        c.1846_1847insT                         ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             430    6    0.014   11C        c.3182 T \> G                           ‐                                      ‐             ‐       Nonsynonymous SNV
  Unclassified             430    6    0.014   intron 2   IVS2‐55insG                             ‐                                      ‐             ‐       ‐
  Unclassified             430    6    0.014   intron 2   IVS2‐55insTG                            ‐                                      ‐             ‐       ‐
  Unclassified             238    3    0.013   11C        c.3072C \> G                            ClinVar\|BED\|ENIGMA                   ‐             ‐       Nonsynonymous SNV
  Unclassified             837    10   0.012   11B        c.2073delA                              ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             179    2    0.011   11A        c.1010delA                              BIC                                    ‐             ‐       Frameshift deletion
  Unclassified             360    4    0.011   17         c.5277+75_5,277+76insC                  ‐                                      ‐             ‐       ‐
  Unclassified             274    3    0.011   11B        c.2252_2253delTG                        ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             403    4    0.010   2          c.43A \> G                              ‐                                      ‐             ‐       Nonsynonymous SNV
  *BRCA2*                                                                                                                                                      
  Pathogenic               107    4    0.037   14         c.7655_7658delTTAA                      BIC\|ClinVar\|BED\|ENIGMA              ‐             ‐       Frameshift deletion
  Pathogenic               180    4    0.022   11A        c.2636_2637delCT                        BIC\|BMD\|ClinVar\|BED\|ENIGMA         ‐             ‐       Frameshift deletion
  Pathogenic               99     2    0.020   11A        c.2339C \> G                            BMD\|ClinVar\|BED\|LOVD\|ENIGMA        ‐             ‐       Frameshift deletion
  Pathogenic               180    3    0.017   11F        c.6715G \> T                            BMD\|ClinVar\|BED\|LOVD\|ENIGMA        ‐             ‐       Stop gain
  Pathogenic               250    4    0.016   9          c.956_957insA                           BIC\|ClinVar\|BED\|BMD\|ENIGMA         ‐             ‐       Frameshift insertion
  Pathogenic               589    9    0.015   22         c.9098_9099insA                         BIC\|BMD\|ClinVar\|BED\|LOVD\|ENIGMA   ‐             ‐       Frameshift insertion
  Pathogenic               133    2    0.015   7          c.755_755delA                           BIC\|ClinVar\|BED\|ENIGMA              ‐             ‐       Frameshift deletion
  Pathogenic               525    6    0.011   23         c.9253delA                              BMD\|ClinVar\|BED\|ENIGMA              ‐             ‐       Frameshift deletion
  Pathogenic               471    5    0.011   11F        c.6449_6450insTA                        BIC\|ClinVar\|BED\|LOVD\|ENIGMA        ‐             ‐       Frameshift insertion
  Pathogenic               496    5    0.010   11E        c.5682C \> A                            BIC\|ClinVar\|BED\|LOVD\|ENIGMA        ‐             ‐       Stop gain
  Likely pathogenic        214    2    0.009   20         c.8800C \> T                            ‐                                      ‐             ‐       Stop gain
  Unclassified             119    2    0.017   15         c.7806‐9 T \> G                         BIC\|BMD\|ClinVar\|BED\|LOVD           ‐             ‐       Intron Variant
  Unclassified             133    2    0.015   11F        c.6645delC                              ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             496    7    0.014   13         c.7178_7179delTG                        ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             149    2    0.013   11A        c.2188_2189insC                         ‐                                      ‐             ‐       Frameshift insertion
  Unclassified             253    3    0.012   27         c.10462A \> G/c.10462 T \> G            ‐                                      ‐             ‐       ‐
  Unclassified             471    5    0.011   18         c.8400_8401del4ins5                     ‐                                      ‐             ‐       ‐
  Unclassified             496    5    0.010   10         c.1545_1546delTT                        ‐                                      ‐             ‐       Frameshift deletion
  Unclassified             623    6    0.010   11F        c.6873_6876delCTCC/c.6873_6876delTGAA   ‐                                      ‐             ‐       Frameshift deletion
                                                                                                                                                               

Case tested refers to the total cases included in each study.

The most significant variants found were the following:*BRCA1* c.5154G \> A. This variant had the highest prevalence of 5.6% (15 out of 266 detected by five studies). It is a stop‐gain pathogenic mutation, present in the BIC, BMD, LOVD, ClinVar, BED databases and was reported as a Chinese founder mutation by a previous study (31).*BRCA1* c.4258C \> T. This variant had a prevalence of 2.5% (3 out of 118), is pathogenic, and is present in the BIC, BMD, LOVD, ClinVar and BED databases.*BRCA1* c.3296delC. This variant had a prevalence of 2.4% (3 out of 124), is pathogenic, and is present in the BIC, BMD, ClinVar, BED and LOVD databases.*BRCA1* c.5533_5540delATTGGGCA/delTACCAGTG. This variant had a prevalence of 2.5% (3 out of 125), is pathogenic, and is absent from other BRCA databases.*BRCA2* c.7655_7658delTTAA. This variant had a prevalence of 3.7% (4 out of 107, reported by four studies), is a pathogenic frameshift deletion and is present in the BIC, ClinVar and BED databases.*BRCA2* c.2636_2637delCT. This variant had a prevalence of 2.2% (4 out of 180), is pathogenic, and is present in the BIC, BMD, ClinVar and BED databases.*BRCA2* c.2339C \> G. This variant had a prevalence of 2% (2 out of 99), is pathogenic, and is present in the BMD, ClinVar, BED and LOVD databases.

Although these high‐frequent *BRCA* mutations suggests the presence of certain potential founder mutations in Chinese population, it is also obvious from the data that there are unlikely to be high‐prevalence founder mutations in the Chinese population as these in the Ashkenazi Jewish population. However, the Chinese population is composed of highly heterogeneous ethnic groups with different genetic features, and even the dominant Han ethnic group is not homogeneous. Therefore, there remains a possibility for the presence of certain high‐prevalence founder mutations in certain specific ethnic groups, and in certain populations located at specific geographical locations.

Comparison within the Chinese population {#ijc32176-sec-0022}
----------------------------------------

It is of interest to know whether *BRCA* ethnic‐specificity exists within the Chinese population, given the fact that it has 56 ethnic groups with divergent genetic backgrounds.[41](#ijc32176-bib-0041){ref-type="ref"} We tested this possibility by using Uygur group as a model. Uygur group is the largest minority group in Xinjiang, northwestern China, with its unique genetic features.[41](#ijc32176-bib-0041){ref-type="ref"} A series of *BRCA* studies have been carried out in Uygur group, with the identification of 70 *BRCA* variants. Of these, 20 *BRCA1* variants and 6 *BRCA2* variant were present only in the Uygur group. Of the 26 Uygur‐specific *BRCA1* variants, one was likely pathogenic, one was uncertain significance, one was likely benign, and 23 remain unclassified (Table [S9](#ijc32176-supitem-0009){ref-type="supplementary-material"}, Supporting Information). The results indicate the presence of Uygur‐specific *BRCA* variants within the Chinese population.

Discussion {#ijc32176-sec-0023}
==========

By using the rich Chinese *BRCA* variation data as a representative of non‐Caucasian populations, our study provides solid evidence to conclude the presence of ethnic‐specific *BRCA* mutation. This likely reflects the human evolutionary history of genetic diversity and environmental adaptation.[11](#ijc32176-bib-0011){ref-type="ref"} The variants shared between different ethnic populations were likely originated before their diversification, whereas the ethnic‐specific variants were likely generated after their diversification. Since *BRCA* reference data plays key roles in identifying the mutation carriers, lack of ethnic‐specific data in the present references implies that they have inadequate power in locating the mutation carriers with non‐Caucasian ethnic background. This is vividly exemplified by the presence of only 16 *BRCA* variants derived from mainland Chinese among the 3,791 *BRCA* variants in the BIC database.[19](#ijc32176-bib-0019){ref-type="ref"} In order to identify the mutation carriers with various ethnic background, ethnic‐specific *BRCA* references need to be developed. Combined usage of both ethnic‐specific and existing *BRCA* reference databases should provide comprehensive identification of *BRCA* mutation carriers in different ethnic populations, a critical step towards precision medicine. Developing ethnic‐specific *BRCA* references will certainly be a challenge both scientifically and financially, but this task needs to be completed sooner or later for the sake of prevention of *BRCA*‐related cancers in the non‐Caucasian populations. The issue of ethnic‐specific germline mutation could also exist in other cancer predisposition genes. Experiences from developing ethnic‐specific *BRCA* references should provide a valuable example to address the same issue in these genes.
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**Table S7E** Chinese BRCA variants shared with Indian population
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**Table S8** High frequent BRCA variants in Chinese population\*
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**Table S9A** Summary of BRCA1 variants in Uygur of Chinese population

**Table S9B**. BRCA variants reported in Xinjiang population
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**Fig S1 Status of *BRCA* studies in Chinese populations.** (A) Regions where *BRCA* testing was conducted. The regions highlighted in yellow are the ones where the tests were conducted between 1999 and 2017; the populations of the Beijing and Shanghai regions are among the most extensively tested, but rapid progress was made in 2016--2017 regarding covering more inland areas (green area). (B) Number of individuals who underwent *BRCA* testing. *BRCA* testing in China was initiated in 1999. The numbers remained steady until 2015, then increased rapidly owing to the use of next‐generation sequencing technologies.
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**Fig S2 Comparison of exon distribution between Chinese and non‐Chinese *BRCA* variants (BIC).** The rate of variation in each exon was calculated by dividing the number of variants in the exon by the total number of variants in *BRCA1* or *BRCA2*. \*p \< 0.05 by Fisher\'s exact test as significance.
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